Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589501 | 1.00 | TSHR (0.50) | TSHRKDM4ELDHASRRALOX15 | |
| SCHEMBL2589498 | 1.00 | TSHR (0.50) | TSHRKDM4ELDHASRRALOX15 | |
| SCHEMBL14401053 | 0.79 | LDHA (0.38) | TSHRKDM4ELDHASRRALOX15 | |
| SCHEMBL24665772 | 0.74 | — | — | |
| SCHEMBL12914531 | 0.74 | — | — | |
| SCHEMBL8367800 | 0.74 | — | — | |
| SCHEMBL14564635 | 0.72 | — | — | |
| SCHEMBL20954529 | 0.72 | — | — | |
| Iodide SCHEMBL7454681 | 0.72 | GLRA1 (0.40) | TSHRKDM4EGLRA1SLC6A9OR51E2 | |
| SCHEMBL3403766 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820190-A | Synthesis method of 4, 6-dichloro-1H-pyrrolo [3,2-c ] pyridine and intermediate thereof | 上海已铼生物科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2563122-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0882044-B1 | 1,4-DIHYDROPYRIDINE COMPOUNDS AS BRADYKININ ANTAGONISTS | PFIZER (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-0777653-B1 | DIHYGROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6131226-A | 2-SUBSTITUTED,3,5-BIS(METHOXYCARBONYL),4-(2,6-DIHALOPHENYL), 6-(1-((SUBSTITUTED)RING)PIPERAZIN-1,4-YLENE-CARBONYLMETHYL)-1, 4-DIHYDROPYRIDINES; FOR TREATING INFLAMMATION, PAIN, VIRAL INFECTIONS, CARDIOVASCULAR DISEASE, ALLERGIES, ASTHMA | PFIZER INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5861402-A | BRADYKININ ANTAGONISTS USEFUL FOR THE TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, COMMON COLD, ALLERGIES, ASTHMA, PANCREATITIS, BURNS, VIRUS INFECTION, HEAD INJURY, MULTIPLE TRAUMA | PFIZER PHARMACEUTICALS, INC. (JP) | 1999-01-19 | — | — | US | disclosed |
| US-5859011-A | Dihydropyridine derivatives as bradykinin antagonist | PFIZER INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0882044-A1 | 1,4-DIHYDROPYRIDINE COMPOUNDS AS BRADYKININ ANTAGONISTS | PFIZER INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997030048-A1 | 1,4-DIHYDROPYRIDINE COMPOUNDS AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1997-08-21 | — | — | WO | disclosed |
| EP-0790239-A1 | Novel 4-phenyl-2-(piperazinyl/perhydrodiazepinyl/aminoalkyl)carbonylmethyl)-1,4-dihydropyridine-3,5-dicarboxylic acid derivatives as bradykinin receptor antagonists | PFIZER INC. (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0777653-A1 | DIHYGROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996006083-A1 | 2-(PIPERAZINYL-1-CARBONYLMETHYL)-1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1996-02-29 | — | — | WO | disclosed |
| WO-1996006082-A1 | DIHYDROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | TSHR 1907/4885KDM4E 569/4885LDHA 1203/4885 |
| US-20130029938-A1 | Chemical Compounds | CYP11B1, GOT2, CYP11B2 | TSHR 2296/4885KDM4E 3520/4885LDHA 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.